Silence Therapeutics (SLN) Restructuring Costs (2025)

Silence Therapeutics (SLN) reported Restructuring Costs of $1.3 million for Q2 2025.

Silence Therapeutics (SLN) Restructuring Costs (2025) Analysis & Trends

Silence Therapeutics (SLN) has 1 years of Restructuring Costs data on file, last reported at $1.3 million in Q2 2025.

For the quarter ending Q2 2025, Restructuring Costs changed N/A year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (changed N/A YoY), and the FY2025 full-year result was $1.3 million, changed N/A from the prior year.
Restructuring Costs steadied at $1.3 million in Q2 2025.
In the past five years, Restructuring Costs ranged from a high of $1.3 million in Q2 2025 to a low of $1.3 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Silence Therapeutics	1.62 Bn	1.49 Bn	411,000.00

Download Data

Date	Value
Jun 30, 2025	1.30 Mn